



Curriculum Vitae

Personal information **Claire Beuneu**

Work experience

1. Employer: Federal Agency for Medicines and Health Products
 - Start date: 032008
 - End date:
 - Position: Non_Clinical Assessor
 - Activities: Assessment of non_clinical data (pharmacology, pharmacokinetics and toxicology) for the purpose of drug registration and clinical trial approval for national and European registration procedures. European and national scientific advices.
 - Country: Belgium
2. Employer: Institute for Medical Immunology (IMI, Pr. Michel Goldman); ULB
 - Start date: 042001
 - End date: 022008
 - Position: Research Associate
 - Activities: Research project "Ductal cells, coagulation, and pancreatic islet transplantation", part of an international project funded by the Juvenile Diabetes Research Foundation.
 - Country: Belgium

Education and training

1. Subject: Paris XI University, Orsay
 - Start date: 1997
 - End date: 2001
 - Qualification: PhD in Biology
 - Organisation: Effects of nitric oxide on de novo biosynthesis of ribonucleotides and deoxyribonucleotides.
 - Country: France
2. Subject: Paris XI University, Orsay
 - Start date: 1992
 - End date: 1997
 - Qualification: Master in Biochemistry and Cellular Biology
 - Organisation: 1996_1997: Nine months work experience (DEA) in the Laboratory "Nitrogen Oxides, inflammation and immunity" Research project: Potentiation of dideoxyinosine (ddI) HIV antiviral activity by hydroxyurea and two of its derivatives
 - Country: France

Additional information

Publications

- Papadouli I, Mueller_Berghaus J, Beuneu C, Ali S, Hofner B, Petavy F, Tzozani K, Miermont A, Norga K, Kholmanskikh O, Leest T, Schuessler_Lenz M, Salmonson T, Gisselbrecht C, Garcia JL, Pignatti F. EMA Review of Axicabtagene Ciloleucef (Yescarta) for the Treatment of Diffuse Large B_Cell Lymphoma. *Oncologist*. 2020 Oct;25(10):894_902.
- Kauffmann F, Van Damme P, Leroux_Roels G, Vandermeulen C, Berthels N, Beuneu C, Mali S. Clinical trials with GMO_containing vaccines in Europe: Status and regulatory framework. *Vaccine*. 2019 Sep 30;37(42):6144_6153.
- Schüssler_Lenz M, Beuneu C, Menezes_Ferreira M, Jekerle V, Bartunek J, Chamuleau S, Celis P, Doevendans P, O'Donovan M, Hill J, Hystad M, Jovinge S, Kyselovič J, Lipnik_Stangelj M, Maciulaitis R, Prasad K, Samuel A, Tenhunen O, Tonn T, Rosano G, Zeiher A, Salmikangas P. Cell_based therapies for cardiac repair: a meeting report on scientific observations and European regulatory viewpoints. *Eur J Heart Fail*. 2016 Feb;18(2):133_41.
- Celis P, Ferry N, Hystad M, Schüssler_Lenz M, Doevendans PA, Flory E, Beuneu C, Reischl I, Salmikangas P. Advanced Therapy Medicinal Products: How to Bring Cell_Based Medicinal Products Successfully to the Market _ Report from the CAT_DGTI_GSCN Workshop at the DGTI Annual Meeting 2014. *Transfus Med Hemother*. 2015 May;42(3):194_9.
- Committee for Advanced Therapies (CAT); CAT Scientific Secretariat, Challenges with advanced therapy medicinal products and how to meet them. *Nature Review Drug Discovery*. 2010, 9(3), p.195_201.
- O Vosters, C Beuneu, M Goldman, V Verhasselt. N_acetylcysteine derivative inhibits CD40_dependent pro_inflammatory properties of human pancreatic duct cells. *Pancreas* 2008, 36(4), p.363_368.
- Stéphanne X, Vosters O, Najimi M, Beuneu C, Dung KN, Wijns W, Goldman M, Sokal EM. Tissue factor_dependent procoagulant activity of isolated human hepatocytes: relevance to liver cell transplantation. *Liver Transpl*. 2007, 13(4), p.599_606
- C Beuneu, O Vosters, Z Ling, D Pipeleers, O Pradier, M Goldman, V Verhasselt. N_Acetylcysteine derivative inhibits procoagulant activity of human islet cells. *Diabetologia* 2007, 50 (2), p.343_347.
- C Beuneu. Transplantation d'îlots et tolérance (review). *Le Courrier de la Transplantation* 2005, juin n°2.
- C Beuneu, O Vosters, B Movahedi, M Rimmelink, I Salmon, D Pipeleers, O Pradier, M Goldman, and V Verhasselt. Human Pancreatic Duct Cells Exert Tissue Factor-Dependent Procoagulant Activity _ Relevance to Islet

Transplantation. Diabetes 2004, 53, p. 1407–1411.

O Vosters, C Beuneu, N Nagy, B Movahedi, E Aksoy, I Salmon, D Pipeleers, M Goldman, V Verhasselt. CD40 expression on human pancreatic duct cells: role in nuclear factor_κB activation and production of pro-inflammatory cytokines. Diabetologia 2004, 47, p. 660_668.

V Verhasselt, O Vosters, C Beuneu, C Nicaise, P Stordeur, M Goldman. Induction of FOXP3-expressing regulatory CD4pos T cells by human mature autologous dendritic cells: Eur.J.Immunol. 2004, 34, p. 762_772.

B Roy, O Guittet, C Beuneu, G Lemaire, M Lepoivre. Depletion of deoxyribonucleoside triphosphate pools in tumor cells by nitric oxide. Free Radic.Biol.Med. 2004, 36, p. 507_516.

C Beuneu, R Auger, M Loffler, A Guissani, G Lemaire, M Lepoivre. Indirect inhibition of mitochondrial dihydroorotate dehydrogenase activity by nitric oxide. Free Radic.Biol.Med. 2000, 28, p. 1206_1213.

B Roy, C Beuneu, P Roux, H Buc, G Lemaire, M Lepoivre. Simultaneous determination of pyrimidine or purine deoxyribonucleoside triphosphates using a polymerase assay. Anal.Biochem. 1999, 269, p. 403_409.

G Lemaire, F J Alvarez_Pachon, C Beuneu, M Lepoivre, J F Petit. Differential cytostatic effects of NO donors and NO producing cells. Free Radic.Biol.Med. 1999, 26, p. 1274_1283.

Projects

Memberships

Member of the Committee for Advanced Therapies (CAT) at the European Medicines Agency (EMA).

Other Relevant Information